References
- Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78. https://doi.org/10.1016/j.ehj.2004.09.014
- Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65. https://doi.org/10.1056/NEJMra035488
- McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7. https://doi.org/10.1056/NEJM199801293380501
- Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65. https://doi.org/10.1161/01.CIR.99.14.1858
- Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900. https://doi.org/10.1016/S0140-6736(02)11024-5
- LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970;4:23-30. https://doi.org/10.1093/cvr/4.1.23
- Jin H, Yang J, Zhang Q, Du J. Epidemiology and clinical management of pulmonary hypertension in children. Korean Circ J 2012;42:513-8. https://doi.org/10.4070/kcj.2012.42.8.513
- Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008;129:163-71. https://doi.org/10.1016/j.ijcard.2008.02.004
- Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow- up and prediction of outcome after surgical correction. Circulation 1987;76:1037-42. https://doi.org/10.1161/01.CIR.76.5.1037
- Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107-22. https://doi.org/10.1161/01.CIR.58.6.1107
- Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 2002;106(12 Suppl 1):I76-81.
- Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11. https://doi.org/10.1161/CIRCULATIONAHA.104.488486
- Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D117-26. https://doi.org/10.1016/j.jacc.2013.10.028
- Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54. https://doi.org/10.1161/CIRCULATIONAHA.106.630715
- Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36. https://doi.org/10.1056/NEJMra040291
- Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with „irreversible“ pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7. https://doi.org/10.1016/j.ijcard.2005.05.062
- Frost AE, Quiñones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24:501-3. https://doi.org/10.1016/j.healun.2004.02.004
- Yamauchi H, Yamaki S, Fujii M, Iwaki H, Tanaka S. Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect. Ann Thorac Surg 2001;72:905-6; discussion 906-7. https://doi.org/10.1016/S0003-4975(00)02537-6
- Eicken A, Balling G, Gildein HP, Genz T, Kaemmerer H, Hess J. Transcatheter closure of a non-restrictive patent ductus arteriosus with an Amplatzer muscular ventricular septal defect occluder. Int J Cardiol 2007;117:e40-2. https://doi.org/10.1016/j.ijcard.2006.10.023
- Khan SA, Gelb BD, Nguyen KH. Evaluation of pulmonary artery banding in the setting of ventricular septal defects and severely elevated pulmonary vascular resistance. Congenit Heart Dis 2006;1:244-50. https://doi.org/10.1111/j.1747-0803.2006.00043.x
- Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J 2007;153(4 Suppl):81-4. https://doi.org/10.1016/j.ahj.2007.01.011
- Allcock RJ, O‘Sullivan JJ, Corris PA. Atrial septostomy for pulmonary arterial hypertension. Heart 2003;89:1344-7. https://doi.org/10.1136/heart.89.11.1344
- Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007;93:974-6. https://doi.org/10.1136/hrt.2006.089185